Bantam Pharmaceutical Completes $25 Million Seed Funding To Finalize Preclinical Development And Prepare For First In Humans Trials
Bantam Pharmaceutical Completes $25 Million Seed Funding To Finalize Preclinical Development And Prepare For First In Humans Trials
09/16/21, 12:03 PM
Money raised
$25 million
Round Type
seed
Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that it has completed a $25 million Seed Funding to finalize its ongoing IND-enabling activities for its lead program, BTM-3566, and consummate preparations for first in human clinical trials. The funding was co-led by Bantam's current investors.
Company Info
Additional Info
Bantam Pharmaceutical is a privately funded biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for difficult-to-treat hematological and solid tumors. The Company's current clinical development strategy is focused on B-cell hematological malignancies with expansion into additional patient cohorts based on responses in biomarker-selected patient populations.